Clinical Trials List
2018-09-01 - 2024-12-19
Phase III
Terminated6
ICD-10C53
Malignant neoplasm of cervix uteri
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 沈書慧 Division of Radiology
- 溫國璋 Division of Obstetrics & Gynecology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- Yen-Hou Chang Division of Obstetrics & Gynecology
- 劉顯慈 Division of Radiology
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- Chi-Mu Chuang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
2 Terminated
Audit
None
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 周宏學 Division of Obstetrics & Gynecology
- Ting-Chang Chang Division of Obstetrics & Gynecology
- 陳威君 Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- Huei-Jean Huang Division of Obstetrics & Gynecology
- Gigin Lin Division of Radiology
- 黃寬仁 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 陳鵬宇 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wei-Chun Chang Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
600 participants
